HC Wainwright Raises Veru (NASDAQ:VERU) Price Target to $3.00

Veru (NASDAQ:VERU) had its price target lifted by HC Wainwright from $2.00 to $3.00 in a research note issued to investors on Monday morning, Benzinga reports. They currently have a buy rating on the stock.

VERU has been the subject of several other research reports. Raymond James assumed coverage on shares of Veru in a report on Thursday, March 28th. They issued an outperform rating and a $3.00 price target for the company. Oppenheimer reissued an outperform rating and issued a $5.00 target price (down from $7.00) on shares of Veru in a research note on Monday, April 15th.

Veru Stock Down 12.3 %

Shares of Veru stock opened at $1.43 on Monday. Veru has a 12 month low of $0.36 and a 12 month high of $1.92. The business has a fifty day simple moving average of $0.99 and a 200 day simple moving average of $0.81. The stock has a market cap of $209.32 million, a PE ratio of -1.91 and a beta of -0.47.

Veru (NASDAQ:VERU) last announced its quarterly earnings results on Monday, April 1st. The company reported ($0.09) EPS for the quarter. Veru had a negative net margin of 405.04% and a negative return on equity of 257.92%. The company had revenue of $2.14 million during the quarter. Analysts expect that Veru will post -0.26 EPS for the current fiscal year.

Institutional Investors Weigh In On Veru

Institutional investors have recently added to or reduced their stakes in the stock. Choreo LLC bought a new stake in shares of Veru in the first quarter valued at about $64,000. Rosalind Advisors Inc. lifted its stake in Veru by 12.5% in the 1st quarter. Rosalind Advisors Inc. now owns 4,500,000 shares of the company’s stock valued at $3,150,000 after acquiring an additional 500,000 shares in the last quarter. 180 Wealth Advisors LLC bought a new position in shares of Veru during the 1st quarter worth approximately $120,000. Perceptive Advisors LLC boosted its holdings in Veru by 412.4% during the fourth quarter. Perceptive Advisors LLC now owns 5,584,699 shares of the company’s stock worth $4,021,000 after purchasing an additional 4,494,821 shares during the last quarter. Finally, Octagon Capital Advisors LP bought a new position in Veru in the fourth quarter valued at $2,736,000. 47.16% of the stock is owned by institutional investors.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.